Ruxolitinib Consistent in Safety, Tolerability Over 52-Weeks

Treating eczema twice-daily with ruxolitinib cream, 1.5% led to positive results for children in the age range of 2 to 11 years.

Related Keywords

Chicago , Illinois , United States , Robert Bissonnette , Innovaderm Research , Innovaderm Research Robert Bissonnette , Revolutionizing Atopic Dermatitis , Maximum Use Trial , Global Assessment , Treatment Success , Dermatology Life Quality Index , Patient Oriented Eczema Measure , Infant Dermatitis Quality ,